- Home
- AXL vs MNMD Comparison
AXL vs MNMD Comparison
Compare AXL & MNMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AXL
- MNMD
- Stock Information
- Founded
- AXL 1994
- MNMD 2019
- Country
- AXL United States
- MNMD United States
- Employees
- AXL N/A
- MNMD N/A
- Industry
- AXL Auto Parts:O.E.M.
- MNMD Pharmaceuticals and Biotechnology
- Sector
- AXL Consumer Discretionary
- MNMD Health Care
- Exchange
- AXL Nasdaq
- MNMD Nasdaq
- Market Cap
- AXL 519.7M
- MNMD 509.2M
- IPO Year
- AXL 1999
- MNMD N/A
- Fundamental
- Price
- AXL $4.44
- MNMD $7.85
- Analyst Decision
- AXL Hold
- MNMD Strong Buy
- Analyst Count
- AXL 7
- MNMD 7
- Target Price
- AXL $5.64
- MNMD $26.29
- AVG Volume (30 Days)
- AXL 3.4M
- MNMD 1.2M
- Earning Date
- AXL 08-08-2025
- MNMD 08-12-2025
- Dividend Yield
- AXL N/A
- MNMD N/A
- EPS Growth
- AXL N/A
- MNMD N/A
- EPS
- AXL 0.18
- MNMD N/A
- Revenue
- AXL $5,929,300,000.00
- MNMD N/A
- Revenue This Year
- AXL N/A
- MNMD N/A
- Revenue Next Year
- AXL N/A
- MNMD N/A
- P/E Ratio
- AXL $25.18
- MNMD N/A
- Revenue Growth
- AXL N/A
- MNMD N/A
- 52 Week Low
- AXL $3.00
- MNMD $4.70
- 52 Week High
- AXL $7.65
- MNMD $10.44
- Technical
- Relative Strength Index (RSI)
- AXL 57.37
- MNMD 61.23
- Support Level
- AXL $4.26
- MNMD $6.95
- Resistance Level
- AXL $4.49
- MNMD $8.11
- Average True Range (ATR)
- AXL 0.15
- MNMD 0.41
- MACD
- AXL 0.03
- MNMD 0.12
- Stochastic Oscillator
- AXL 92.73
- MNMD 85.27
About AXL American Axle & Manufacturing Holdings Inc.
American Axle & Mfg Holdings Inc is engaged in manufacturing, engineering, designing, and validation of driveline systems and related components and chassis modules for light trucks, SUVs, crossover vehicles, passenger cars, and commercial vehicles. The company's segment includes Driveline and Metal Forming. It generates maximum revenue from the Driveline segment.
About MNMD Mind Medicine (MindMed) Inc.
Mind Medicine Inc. is a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders. It is developing a pipeline of product candidates targeting neurotransmitter pathways that play key roles in brain health disorders. This includes explicitly pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM120 and MM402, as its key product candidates. The MM120 is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that is being developed to treat generalized anxiety disorder and clinical depressive disorder, and the MM402 is a proprietary form of the R-enantiomer of 3,4-methylenedioxymethamphetamine (MDMA), being developed to treat autism spectrum disorder (ASD).